Announcements Trials
Browse Landscape

Phase

Phase 1/2 9Phase 1 9Phase 2 6Phase 3 3

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 26Leukemia, Lymphocytic, Chronic, B-Cell 24Neoplasms 8Leukemia 4Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Chromosome 17 deletion 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Mantle-Cell 2Leukemia, B-Cell 2Venentoclax 1Tumor Lysis Syndrome 1Pathologic Complete Response 1Lymphoma, B-Cell 1Hematologic Neoplasms 1Hematologic Diseases 1

Interventions

Dexamethasone 169Bortezomib 92Lenalidomide 85daratumumab 44Thalidomide 44pomalidomide 43Melphalan 40Cyclophosphamide 33carfilzomib 29Calcium Dobesilate 27Prednisone 19Doxorubicin 16elotuzumab 14isatuximab 12Filgrastim 12ixazomib 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10belantamab mafodotin 9Granulocyte Colony-Stimulating Factor 9Zoledronic Acid 8selinexor 7dexamethasone acetate 7Epoetin Alfa 7Etoposide 6fludarabine 5Cisplatin 5Carmustine 5iberdomide 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Multiple Myeloma × venetoclax × Clear all
NCT03844048 2026-05-13

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

AbbVie

Phase 3 Active not recruiting
165 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03539744 2025-06-19

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

AbbVie

Phase 3 Active not recruiting
265 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

NCT02755597 2023-08-22

Bellini

AbbVie

Phase 3 Completed
291 enrolled 24 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡